191 related articles for article (PubMed ID: 7906414)
21. Phosphorothioate oligonucleotides inhibit human immunodeficiency virus type 1 fusion by blocking gp41 core formation.
Vaillant A; Juteau JM; Lu H; Liu S; Lackman-Smith C; Ptak R; Jiang S
Antimicrob Agents Chemother; 2006 Apr; 50(4):1393-401. PubMed ID: 16569857
[TBL] [Abstract][Full Text] [Related]
22. Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus.
Matsukura M; Shinozuka K; Zon G; Mitsuya H; Reitz M; Cohen JS; Broder S
Proc Natl Acad Sci U S A; 1987 Nov; 84(21):7706-10. PubMed ID: 3499613
[TBL] [Abstract][Full Text] [Related]
23. Mode of action of 5'-linked cholesteryl phosphorothioate oligodeoxynucleotides in inhibiting syncytia formation and infection by HIV-1 and HIV-2 in vitro.
Stein CA; Pal R; DeVico AL; Hoke G; Mumbauer S; Kinstler O; Sarngadharan MG; Letsinger RL
Biochemistry; 1991 Mar; 30(9):2439-44. PubMed ID: 1705817
[TBL] [Abstract][Full Text] [Related]
24. Role of the V2, V3, and CD4-binding domains of GP120 in curdlan sulfate neutralization sensitivity of HIV-1 during infection of T lymphocytes.
Jagodzinski PP; Wustner J; Kmieciak D; Wasik TJ; Fertala A; Sieron AL; Takahashi M; Tsuji T; Mimura T; Fung MS; Gorny MK; Kloczewiak M; Kaneko Y; Kozbor D
Virology; 1996 Dec; 226(2):217-27. PubMed ID: 8955041
[TBL] [Abstract][Full Text] [Related]
25. Newly designed six-membered azasugar nucleotide-containing phosphorothioate oligonucleotides as potent human immunodeficiency virus type 1 inhibitors.
Lee DS; Jung KE; Yoon CH; Lim H; Bae YS
Antimicrob Agents Chemother; 2005 Oct; 49(10):4110-20. PubMed ID: 16189087
[TBL] [Abstract][Full Text] [Related]
26. Properties of quadruplex oligonucleotides with anti-HIV-1 activity.
Tamura Y; Yoshida M; Suzuki J; Hiratou T; Miyano-Kurosaki N; Takai K; Takaku H
Nucleic Acids Symp Ser; 2000; (44):181-2. PubMed ID: 12903328
[TBL] [Abstract][Full Text] [Related]
27. Phosphorothioate G3T4G3 motifs inhibits the early stage of HIV-1 infection.
Suzuki J; Miyano-Kurosaki N; Takeuchi H; Tamura Y; Kawai G; Takai K; Tanaka Y; Tanaka R; Yamamoto N; Takaku H
Nucleic Acids Symp Ser; 1999; (42):227-8. PubMed ID: 10780462
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of human immunodeficiency virus infection of CD4+ cells by CD4-free glycopeptides from monocytic U937 cells.
Mbemba E; Carré V; Atemezem A; Saffar L; Gluckman JC; Gattegno L
AIDS Res Hum Retroviruses; 1996 Jan; 12(1):47-53. PubMed ID: 8825618
[TBL] [Abstract][Full Text] [Related]
29. SPC3, a synthetic peptide derived from the V3 domain of human immunodeficiency virus type 1 (HIV-1) gp120, inhibits HIV-1 entry into CD4+ and CD4- cells by two distinct mechanisms.
Yahi N; Fantini J; Baghdiguian S; Mabrouk K; Tamalet C; Rochat H; Van Rietschoten J; Sabatier JM
Proc Natl Acad Sci U S A; 1995 May; 92(11):4867-71. PubMed ID: 7761414
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of HIV-1 in cell culture by synthetic humate analogues derived from hydroquinone: mechanism of inhibition.
Schneider J; Weis R; Männer C; Kary B; Werner A; Seubert BJ; Riede UN
Virology; 1996 Apr; 218(2):389-95. PubMed ID: 8610466
[TBL] [Abstract][Full Text] [Related]
31. Antiviral effects of milk proteins: acylation results in polyanionic compounds with potent activity against human immunodeficiency virus types 1 and 2 in vitro.
Swart PJ; Kuipers ME; Smit C; Pauwels R; deBéthune MP; de Clercq E; Meijer DK; Huisman JG
AIDS Res Hum Retroviruses; 1996 Jun; 12(9):769-75. PubMed ID: 8738428
[TBL] [Abstract][Full Text] [Related]
32. Novel, negatively charged, human serum albumins display potent and selective in vitro anti-human immunodeficiency virus type 1 activity.
Jansen RW; Schols D; Pauwels R; De Clercq E; Meijer DK
Mol Pharmacol; 1993 Nov; 44(5):1003-7. PubMed ID: 7902528
[TBL] [Abstract][Full Text] [Related]
33. Mechanism of the inhibitory effect of curdlan sulfate on HIV-1 infection in vitro.
Jagodzinski PP; Wiaderkiewicz R; Kurzawski G; Kloczewiak M; Nakashima H; Hyjek E; Yamamoto N; Uryu T; Kaneko Y; Posner MR
Virology; 1994 Aug; 202(2):735-45. PubMed ID: 7913276
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of gp120-CD4 interaction and human immunodeficiency virus type 1 infection in vitro by pyridoxal 5'-phosphate.
Guo L; Heinzinger NK; Stevenson M; Schopfer LM; Salhany JM
Antimicrob Agents Chemother; 1994 Oct; 38(10):2483-7. PubMed ID: 7530934
[TBL] [Abstract][Full Text] [Related]
35. Resistance of the human immunodeficiency virus to the inhibitory action of negatively charged albumins on virus binding to CD4.
Cabrera C; Witvrouw M; Gutiérrez A; Clotet B; Kuipers ME; Swart PJ; Meijer DK; Desmyter J; De Clercq E; Esté JA
AIDS Res Hum Retroviruses; 1999 Nov; 15(17):1535-43. PubMed ID: 10580404
[TBL] [Abstract][Full Text] [Related]
36. Membrane-interactive phospholipids inhibit HIV type 1-induced cell fusion and surface gp160/gp120 binding to monoclonal antibody.
Krugner-Higby L; Goff D; Edwards T; Iyer N; Neufeld J; Kute T; Morris-Natschke S; Ishaq K; Piantadosi C; Kucera LS
AIDS Res Hum Retroviruses; 1995 Jun; 11(6):705-12. PubMed ID: 7576930
[TBL] [Abstract][Full Text] [Related]
37. Partial inhibition of yellow fever virus replication in vitro with different phosphorothioate oligodeoxyribonucleotides.
Tolou H; Puggelli H; Tock F; Durand JP
Acta Virol; 1996 Apr; 40(2):73-9. PubMed ID: 8886115
[TBL] [Abstract][Full Text] [Related]
38. Human CD38 interferes with HIV-1 fusion through a sequence homologous to the V3 loop of the viral envelope glycoprotein gp120.
Savarino A; Bensi T; Chiocchetti A; Bottarel F; Mesturini R; Ferrero E; Calosso L; Deaglio S; Ortolan E; Buttò S; Cafaro A; Katada T; Ensoli B; Malavasi F; Dianzani U
FASEB J; 2003 Mar; 17(3):461-3. PubMed ID: 12551845
[TBL] [Abstract][Full Text] [Related]
39. Suppression of human immunodeficiency virus type 1 activity in vitro by oligonucleotides which form intramolecular tetrads.
Rando RF; Ojwang J; Elbaggari A; Reyes GR; Tinder R; McGrath MS; Hogan ME
J Biol Chem; 1995 Jan; 270(4):1754-60. PubMed ID: 7829511
[TBL] [Abstract][Full Text] [Related]
40. [The antiviral action of recombinant forms of the human T-lymphocyte CD4 receptor].
Zverev VV; Maliushova VV; Sidorov AV; Pugach AV; Shukhmina NR; Pille ER; Mel'nikova NL; Andzhaparidze OG
Vopr Virusol; 1994; 39(2):56-9. PubMed ID: 7517083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
